Novocuff is a technology company.
Novocuff has raised $26.0M across 1 funding round.
Novocuff has raised $26.0M in total across 1 funding round.
Novocuff is a medical device company founded in 2021 in San Luis Obispo, California, developing the Novocuff Cervical Control System (CCS), a simple silicone device inserted vaginally to stabilize and close the cervix.[1][2][4] It targets preterm premature rupture of membranes (PPROM) and cervical shortening, leading causes of preterm birth—the top cause of infant mortality worldwide, linked to about 1 million deaths in 2020 per WHO data—by retaining amniotic fluid and extending pregnancy in both singleton and multiple gestation cases.[1][2][3] The company serves obstetricians, hospitals, and pregnant women at high risk, solving a critical gap where preterm births affect 15 million cases globally annually.[1][4] Now at Series A stage with $26.07M raised (including a $26M oversubscribed round led by AXA IM Alts 10 months ago), Novocuff shows strong growth momentum via FDA pursuits, patents in obstetrics and women's health, and investors like Laborie, Laerdal Million Lives Fund, and March of Dimes.[1][2]
Novocuff emerged from personal tragedy and engineering ingenuity. CTO and co-founder Donald invented the core device after his twin daughters were born prematurely three years ago; driven by mechanical engineering expertise, he prototyped a solution to prevent preterm labor while they recovered and thrived.[4] Seeking commercialization help, he pitched former colleague Amy (Amelia) Degenkolb—an engineer from Alydia Health (formerly InPress Technologies), where she helped develop the Jada System for postpartum hemorrhage—at a San Luis Obispo coffee shop in 2021; she joined as CEO and co-founder after reviewing just one page, handling business, fundraising, and FDA efforts while Donald led product development.[1][4]
The startup incubated at Cal Poly's CIE, raised a $2M seed, and hit a milestone with the oversubscribed $26M Series A, fueled by Degenkolb's prior success at Alydia (backed by AXA).[1][4] Early traction includes 2 patents and a design optimized for global use, even in low-resource settings without specialized physicians.[1][4]
Novocuff rides the maternal-fetal health tech wave, addressing preterm birth amid rising global focus on women's health and neonatal outcomes—exacerbated by 15M annual cases and 1M infant deaths.[1][2][4] Timing aligns with post-pandemic emphasis on preventable complications, FDA-friendly medtech innovations, and investor interest in scalable devices (e.g., AXA's Alydia follow-on).[1] Market tailwinds include Laborie's OB/GYN dominance and funds like Laerdal targeting "million lives," plus demand in emerging markets where physician shortages amplify needs.[2][4] It influences the ecosystem by pioneering non-invasive preterm interventions, potentially shifting standards of care and inspiring copycats in femtech.[1][2]
Novocuff is poised for FDA clearance, U.S. commercialization, and global scale—leveraging simple design for rapid adoption in diverse settings.[1][4] Key trends like AI diagnostics and telemedicine will amplify its reach, while climate/health crises boost preterm risk awareness. Expect partnerships (e.g., Laborie distribution) and Series B by 2026, evolving from niche innovator to preterm standard-setter, saving millions of infant lives as its founders beat the odds with their own daughters.[2][4] This device could redefine maternal tech, turning personal drive into planetary impact.
Novocuff has raised $26.0M in total across 1 funding round.
Novocuff's investors include Adjuvant Capital, Laerdal Million Lives Fund.
Novocuff has raised $26.0M across 1 funding round. Most recently, it raised $26.0M Series A in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $26.0M Series A | Adjuvant Capital, Laerdal Million Lives Fund |